Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Pulmonary/Respiratory Diseases | Family Medicine
Disease Category: Non-Small Cell Lung Cancer
Location: United States, IL
Clinical Trial Details
Research Study Summary
A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin in Patients with Squamous Cell Carcinoma of the Lung (single-arm, open label, Phase 2 study of REOLYSIN® combined with paclitaxel and carboplatin every 3 weeks)
The primary goal of this study is to see if the treatment with the most common chemotherapy treatment (paclitaxel, carboplatin) with REOLYSIN® is helpful in treating your type of cancer. REOLYSIN® is a new form of cancer treatment that uses a type of virus called reovirus. This virus is commonly found in natural situations throughout the world (such as ponds and ditches) and may be associated with only very minor breathing or stomach upsets in humans. Infection of cancer cells by this virus can slow the cancer lesion growth and kill cancerous cells. Tests have already been carried out using REOLYSIN® in humans and few side effects have been seen. It is known that the combination of paclitaxel and carboplatin can benefit patients with several different tumor types.
In this study, REOLYSIN® will be given through a small plastic tube into your vein (intravenous infusion) and you will also be treated with both paclitaxel and carboplatin in the same way. The dose of REOLYSIN and chemotherapy you will receive will stay the same during the time you are on this study. Paclitaxel and carboplatin is a common treatment for squamous cell carcinoma of the lung.
Please contact Alexian Brothers for more information on participation.
To Learn more
Both Male and Female
Date Last Changed:
July 22, 2013
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these